Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of SHR6390 (Dalpiciclib) in Healthy Chinese Volunteers
NCT05354336Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jun 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dalpiciclib in breast cancer (3 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Peak Plasma Concentration at 12 days, Area under the plasma concentration versus time curve from time 0 to time t at 12 days and 1 more. Started Jun 2019; status: completed.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05354336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05354336.